← Human Trials & Peer-Reviewed Studies
A Dietary Supplement in the Management of Patients with Lumbar Osteochondrosis: A Randomized, Double-Blinded, Placebo-Controlled Study.
Plain-language guide to PMID 39203831 (2024): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 39203831
- Journal
- Nutrients
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Laky B et al. (8 authors)
- DOI
- 10.3390/nu16162695
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
Magnetic resonance imaging (MRI) was used to evaluate degenerative changes of intervertebral discs (IVD) including Pfirrmann grades as well as three-dimensional (3D) volume measurements.
Why It Was Studied
Various nutritional supplements are available over the counter, yet few have been investigated in randomized controlled trials.
The rationale for using the specific mix of nutritional substances including collagen type II, hyaluronic acid, n-acetyl-glucosamine, bamboo extract, L-lysine, and vitamin C is the assumption that combining naturally occurring ingredients of the intervertebral disc would maintain spine function.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
What Was Measured
Patient-Reported Outcome Measures (PROMs) included the Oswestry Disability Index (ODI), the visual analogue scale for pain (pVAS), short form-12 (SF-12) physical and mental component summary subscale scores (PCS and MCS, respectively), and global physical activity questionnaire (GPAQ).
Topics PubMed links to this paper include Dietary Supplements, Lumbar Vertebrae, Intervertebral Disc Degeneration, Magnetic Resonance Imaging, Patient Reported Outcome Measures, Osteochondrosis and Spinal Osteochondrosis.
The authors tagged it with the keywords L-lysine, bamboo extract, collagen type II, hyaluronic acid, lower back pain and magnetic resonance images (MRI).
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The publication is from 2024 (Nutrients), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.